Antibody engineering and its applications in tumor targeting and intracellular immunization.
During the last decade, recombinant antibody engineering has emerged as one of the most promising approaches for the design, selection and production of molecules for basic research, medicine and the pharmaceutical industry. This MiniReview describes the major findings that have led to the development of this powerful technique, with an emphasis on the use of Escherichia coli and filamentous phage as a tool allowing powerful selection procedures from large libraries as well as the use of intracellular expression of antibody fragments as a new class of neutralizing molecules with a potential use in therapy. The future of these rapidly evolving technologies is discussed.
Department of Pathology, Maastricht University, The Netherlands.
P
P
Chames
D
D
Baty
D000818:Animals; D000906:Antibodies / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007114:Immunization; D018796:Immunoconjugates; D007128:Immunoglobulin Fragments / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D019151:Peptide Library; D015202:Protein Engineering
D000906:Antibodies; D018796:Immunoconjugates; D007128:Immunoglobulin Fragments; D019151:Peptide Library